TY - JOUR T1 - CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 671 LP - 674 DO - 10.1136/annrheumdis-2019-216607 VL - 79 IS - 5 AU - Satoshi Takanashi AU - Yuko Kaneko AU - Tsutomu Takeuchi Y1 - 2020/05/01 UR - http://ard.bmj.com/content/79/5/671.abstract N2 - The primary therapeutic target for rheumatoid arthritis is remission, assessed using validated composited measures.1 Currently, index-based remission frequently used in clinical practice are disease activity (CDAI) and Disease Activity Score for 28 joints (DAS28). Generally, it has been reported that CDAI is more stringent than DAS28 in assessing clinical remission.1 2 However, this confirmation was mainly derived from trial results. Hence, this study aimed to investigate the real-world performance of CDAI and DAS28-erythrocyte sedimentation rate (ESR).In total, 1585 consecutive patients with rheumatoid arthritis (mean age: 64 years, sex: 84% were women, mean disease duration: 12.0 years) in Keio University Hospital were reviewed cross-sectionally. Current treatments were conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) alone, tumour necrosis factor inhibitors (TNFi), interleukin 6 receptor inhibitors (IL-6i), cytotoxic T-lymphocyte associated antigen (CTLA)-4Ig and janus kinase inhibitors (JAKi) in 39.2%, 29.0%, 22.8%, 7.1% and 1.8% patients, respectively. Definition of cut-offs of each composite scores was following; remission, CDAI ≤2.8, DAS28-ESR <2.6; low disease activity, CDAI ≤10, DAS28-ESR <3.2; moderate disease activity; CDAI ≤22, DAS28-ESR≤5.1; high disease activity, CDAI >22, DAS28-ESR >5.1.First, we focused on the patients in CDAI remission (62.7% in all, 66.4% treated with csDMARDs, 65.8% treated with TNFi, 58.6% treated with IL-6i, … ER -